1 Min Read
June 7 (Reuters) - Protalix Biotherapeutics Inc:
* Protalix biotherapeutics announces Phase II clinical trial results for Alidornase Alfa in cystic fibrosis presented at the 40th EUROPEAN cystic fibrosis society conference
* "Alidornase Alfa was well tolerated with no serious adverse events reported"
* Protalix Biotherapeutics Inc says clinical data demonstrate over 70% reduction in presence of pseudomonas Source text for Eikon: Further company coverage: